

GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030

> Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494

Web: www.gsk-india.com
Email: askus@gsk.com

31st August 2024

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (East) Mumbai - 400051

Dear Sir,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we would like to inform you that the Company has received an below mentioned orders on 30th August 2024. The relevant details to be is disclosed is as under:

Srno	Particulars	Details
1	Name of the authority	Superintendent Range – I, Division – V, Central GST, Goa
		Joint Commissioner Commercial Tax Department, Rajasthan
2	Nature and details of the action(s) taken, initiated or order(s) passed	Order dated 28 August 2024 passed under Section 73 of CGST Act, 2017 for the FY 2019-20 Tax - Rs.7,27858, Interest - Not quantified, Penalty - Rs.72,785
		Order dated 30 August 2024 passed under Section 73 of CGST Act, 2017 for the FY 2019-20 Tax - Rs.23,78,358, Interest - Rs.18,68,412 Penalty - Rs.4,91,901
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	30 th August 2024
4	Details of violation(s) / contravention(s) committed or alleged to be committed	The officer has raised demand in relation to GST credit mismatch between Company's GST returns vis-à-vis details reported by suppliers
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No impact on GSK. The Company believes that the said demand is not maintainable and will be filing an Appeal against the said Order

Kindly take the same on the record.

Thanking you,

Yours faithfully

For GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary

CIN: L24239MH1924PLC001151